Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma

Immunotherapy

Volumn 8, Issue 12, 2016, Pages 1363-1369

  Simonelli, Matteo ^a   Tommaso, Luca DI ^a,b   Baretti, Marina ^a   Santoro, Armando ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b HUMANITAS UNIVERSITY   (Italy)

Author keywords

anti PD 1 L 1 agents; hepatitis; immune related adverse events

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; FOTEMUSTINE; GAMMA GLUTAMYLTRANSFERASE; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLPREDNISOLONE; NIVOLUMAB; PREDNISONE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; MGMT PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; COLITIS; CRANIOTOMY; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; HEADACHE; HISTOLOGY; HUMAN; HUMAN TISSUE; IDH1 GENE; LIVER BIOPSY; MAINTENANCE THERAPY; MALE; MGMT GENE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SPEECH DISORDER; TOXIC HEPATITIS; ANALOGS AND DERIVATIVES; AUTOIMMUNITY; BRAIN NEOPLASMS; CANCER STAGING; CHEMICAL AND DRUG INDUCED LIVER INJURY; COMPLICATION; DNA METHYLATION; GENETICS; IMMUNOLOGY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOIMMUNITY; BRAIN NEOPLASMS; CHEMICAL AND DRUG INDUCED LIVER INJURY; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; NEOPLASM STAGING; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 85007158514     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0057     Document Type: Article

References (22)

1. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
2. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 16, 375-384 (2015).
3. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532 (2015).
4. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123-135 (2015).
5. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
6. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803-1813 (2015).
7. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26(12), 2375-2391 (2015).
8. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
9. Ribas A, Kefford R, Marshall MA et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31, 616-622 (2013).
10. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am. Soc. Clin. Oncol. Educ. Book. 35, 76-83 (2015)
11. Kleiner DE, Berman D. Pathologic changes in ipilimumabrelated hepatitis in patients with metastatic melanoma. Dig. Dis. Sci. 57, 2233-2240 (2012).
12. Kim KW, Ramaiya NH, Krajewski KM et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest. New Drugs 31, 1071-1077 (2013).
13. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, Phase 2, dose-ranging study. Lancet Oncol. 11, 155-164 (2010).
14. Bernardo SG, Moskalenko M, Pan M et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res. 23, 47-54 (2013).
15. El-Khoueiry AB, Melero I, Crocenzi TS et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J. Clin. Oncol. 33, 15 (2015).
16. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
17. Ribas A, Hodi FS, Callahan M et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365-1366 (2013).
18. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
19. Fontana RJ, Seeff LB, Andrade RJ et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 52, 730-42 (2010).
20. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23(25), 6043-6053 (2005).
21. Chmiel KD, Suan D, Liddle C et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J. Clin. Oncol. 29, e237-e240 (2011).
22. Melero I, Berman DM, Aznar MA et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15, 457-472 (2015).